Biomarkers for predicting the sensitivity of cancer cells to TRAIL-R1 agonistic monoclonal antibody

Cancer Letters

Volumn 292, Issue 2, 2010, Pages 269-279

  Araki, Shinsuke ^a   Nakayama, Yusuke ^a   Hori, Akira ^a   Yoshimura, Koji ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Apoptosis; Predictive biomarker; TRAIL R1 antibody; TRAIL resistance

Indexed keywords

BIOLOGICAL MARKER; CASPASE 8; PROTEIN AIM1; PROTEIN SP140L; PROTEIN STK17B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND R1; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; PREDICTION; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY ANALYSIS; GENE SILENCING; IMMUNOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; POLYMERASE CHAIN REACTION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77951923134     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.12.007     Document Type: Article

References (47)

1. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14:737-744.
2. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl. J. Med. 2001, 344:1031-1037.
3. Lipton A., Ali S.M., Leitzel K., Demers L., Chinchilli V., Engle L., Harvey H.A., Brady C., Nalin C.M., Dugan M., Carney W., Allard J. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol. 2002, 20:1467-1472.
4. Albanell J., Rojo F., Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 2001, 28:56-66.
5. Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., Mohsin S., Osborne C.K., Chamness G.C., Allred D.C., O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362:362-369.
6. Cheok M.H., Yang W., Pui C.H., Downing J.R., Cheng C., Naeve C.W., Relling M.V., Evans W.E. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat. Genet. 2003, 34:85-90.
7. Okutsu J., Tsunoda T., Kaneta Y., Katagiri T., Kitahara O., Zembutsu H., Yanagawa R., Miyawaki S., Kuriyama K., Kubota N., Kimura Y., Kubo K., Yagasaki F., Higa T., Taguchi H., Tobita T., Akiyama H., Takeshita A., Wang Y.H., Motoji T., Ohno R., Nakamura Y. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol. Cancer Ther. 2002, 1:1035-1042.
8. Hofmann W.K., de Vos S., Elashoff D., Gschaidmeier H., Hoelzer D., Koeffler H.P., Ottmann O.G. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002, 359:481-486.
9. Huang F., Reeves K., Han X., Fairchild C., Platero S., Wong T.W., Lee F., Shaw P., Clark E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007, 67:2226-2238.
10. McLean L.A., Gathmann I., Capdeville R., Polymeropoulos M.H., Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin. Cancer Res. 2004, 10:155-165.
11. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996, 271:12687-12690.
12. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5:157-163.
13. Evdokiou A., Bouralexis S., Atkins G.J., Chai F., Hay S., Clayer M., Findlay D.M. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int. J. Cancer 2002, 99:491-504.
14. LeBlanc H.N., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003, 10:66-75.
15. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
16. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12:599-609.
17. Eggert A., Grotzer M.A., Zuzak T.J., Wiewrodt B.R., Ho R., Ikegaki N., Brodeur G.M. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 2001, 61:1314-1319.
18. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996, 86:147-157.
19. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997, 275:1132-1136.
20. Chuntharapai A., Dodge K., Grimmer K., Schroeder K., Marsters S.A., Koeppen H., Ashkenazi A., Kim K.J. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 2001, 166:4891-4898.
21. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., Zhang H., Mountz J.D., Koopman W.J., Kimberly R.P., Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 2001, 7:954-960.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
23. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
24. Nutt C.L., Mani D.R., Betensky R.A., Tamayo P., Cairncross J.G., Ladd C., Pohl U., Hartmann C., McLaughlin M.E., Batchelor T.T., Black P.M., von Deimling A., Pomeroy S.L., Golub T.R., Louis D.N. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003, 63:1602-1607.
25. Koziol J.A., Zhang J.Y., Casiano C.A., Peng X.X., Shi F.D., Feng A.C., Chan E.K., Tan E.M. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res. 2003, 9:5120-5126.
26. Deiss L.P., Feinstein E., Berissi H., Cohen O., Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev. 1995, 9:15-30.
27. Inbal B., Shani G., Cohen O., Kissil J.L. Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol. Cell Biol. 2000, 20:1044-1054.
28. Kawai T., Matsumoto M., Takeda K., Sanjo H., Akira S. ZIP kinase, a novel serine/threonine kinase which mediates apoptosis. Mol. Cell Biol. 1998, 18:1642-1651.
29. Kawai T., Nomura F., Hoshino K., Copeland N.G., Gilbert D.J., Jenkins N.A., Akira S. Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity. Oncogene 1999, 18:3471-3480.
30. Sanjo H., Kawai T., Akira S. DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. J. Biol. Chem. 1998, 273:29066-29071.
31. Yang W., Monroe J., Zhang Y., George D., Bremer E., Li H. Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells. Cancer Lett. 2006, 243:217-227.
32. Van Geelen C.M., de Vries E.G., de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Update 2004, 7:345-358.
33. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005, 12:228-237.
34. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
35. Yoshida T., Shiraishi T., Horinaka M., Wakada M., Sakai T. Glycosylation modulates TRAIL-R1/death receptor 4 prote. Oncol. Rep. 2007, 18:1239-1242.
36. Mao J., Qiao X., Luo H., Wu J. Transgenic drak2 overexpression in mice leads to increased T cell apoptosis and compromised memory T cell development. J. Biol. Chem. 2006, 281:12587-12595.
37. Kuwahara H., Nakamura N., Kanazawa H. Nuclear localization of the serine/threonine kinase DRAK2 is involved in UV-induced apoptosis. Biol. Pharm. Bull. 2006, 29:225-233.
38. Bernardi R., Pandolfi P.P. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 2003, 22:9048-9057.
39. Everett R.D. Interactions between DNA viruses, ND10 and the DNA damage response. Cell Microbiol. 2006, 8:365-374.
40. Hofmann T.G., Will H. Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ. 2003, 10:1290-1299.
41. Takahashi Y., Lallemand-Breitenbach V., Zhu J., de The H. PML nuclear bodies and apoptosis. Oncogene 2004, 23:2819-2824.
42. Rajini B., Graham C., Wistow G., Sharma Y. Stability, homodimerization, and calcium-binding properties of a single, variant betagamma-crystallin domain of the protein absent in melanoma 1 (AIM1). Biochemistry 2003, 42:4552-4559.
43. Ray M.E., Wistow G., Su Y.A., Meltzer P.S., Trent J.M. AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc. Natl. Acad. Sci. USA 1997, 94:3229-3234.
44. Morris S.R., Carey L.A. Gene expression profiling in breast cancer. Curr. Opin. Oncol. 2007, 19:547-551.
45. Cronin M., Sangli C., Liu M.L., Pho M., Dutta D., Nguyen A., Jeong J., Wu J., Langone K.C., Watson D. Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 2007, 53:1084-1091.
46. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield M.R., Hayes D.F., Bast R.C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25:5287-5312.
47. Hyams D.M. Understanding tumor profiling and assessing treatment. Manag. Care. 2008, 17:4-8. Discussion 17-18.